Skip to main content
SpringerLink
Log in

Essential news and practice changing trials in oesophageal, gastroesophageal junction and gastric cancer in 2021

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

In this short review we aim to summarize the highlights in gastric, gastroesophageal junction and oesophageal cancer in 2021. We will discuss practice changing studies and potential guideline changes based on these trials, with focus on the latest developments regarding checkpoint inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    Article  Google Scholar 

  2. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–86.

    Article  Google Scholar 

  3. Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–203.

    Article  CAS  Google Scholar 

  4. Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–71.

    Article  CAS  Google Scholar 

  5. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40.

    Article  CAS  Google Scholar 

  6. Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD‑1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727–30.

    Article  CAS  Google Scholar 

  7. Zhao JJ, Yap DWT, Chan YH, Tan BKJ, Teo CB, Syn NL, et al. Low programmed death-ligand 1‑expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma. J Clin Oncol. 2022;40(4):392–402.

    Article  CAS  Google Scholar 

  8. Leone AG, Petrelli F, Ghidini A, Raimondi A, Smyth EC, Pietrantonio F. Efficacy and activity of PD‑1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score. ESMO Open. 2022;7(1):100380.

    Article  CAS  Google Scholar 

  9. Shen L, Lu Z, Wang J, Shu Y, Kong L, Yang L, et al. Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: first results of the phase III ORIENT-15 study. Ann Oncol. 2021;32(5):1283–346.

    Google Scholar 

  10. Xu R, Wang F, Cui C, Yao J, Zhang Y, Wang G, et al. JUPITER-06: a randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC). Ann Oncol. 2021;32(5):1040–75.

    Google Scholar 

  11. Narita Y, Sasaki E, Masuishi T, Taniguchi H, Kadowaki S, Ito S, et al. PD-L1 immunohistochemistry comparison of 22C3 and 28‑8 assays for gastric cancer. J Gastrointest Oncol. 2021;12(6):2696–705.

    Article  Google Scholar 

  12. Zhou KI, Peterson B, Serritella A, Thomas J, Reizine N, Moya S, et al. Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clin Cancer Res. 2020;26(24):6453–63.

    Article  CAS  Google Scholar 

  13. Cancer Genome A, Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.

    Article  Google Scholar 

  14. Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, Brigham and Women’s Hospital, Broad Institute; Brown University, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169–75.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine II, Feldkirch Academic Teaching Hospital, Carinagasse 47, 6800, Feldkirch, Austria

    Patrick Reimann & Thomas Winder

  2. Private University of the Principality of Liechtenstein, Triesen, Principality of Liechtenstein, Liechtenstein

    Patrick Reimann

  3. University of Zurich, Zurich, Switzerland

    Thomas Winder

Authors
  1. Patrick Reimann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Winder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Reimann.

Ethics declarations

Conflict of interest

P. Reimann and T. Winder declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reimann, P., Winder, T. Essential news and practice changing trials in oesophageal, gastroesophageal junction and gastric cancer in 2021. memo 15, 238–242 (2022). https://doi.org/10.1007/s12254-022-00809-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-022-00809-6

Keywords

Search

Navigation